Clinical significance and regulation of the costimulatory molecule B7-H1 in pancreatic cancer - PubMed (original) (raw)

. 2008 Sep 8;268(1):98-109.

doi: 10.1016/j.canlet.2008.03.056. Epub 2008 May 16.

Affiliations

• PMID: 18486325
• DOI: 10.1016/j.canlet.2008.03.056

Clinical significance and regulation of the costimulatory molecule B7-H1 in pancreatic cancer

Martin Loos et al. Cancer Lett. 2008.

Abstract

We investigated the expression pattern and clinical significance of the costimulatory ligands B7-1, B7-2, B7-H1, and B7-DC, and their counter-receptors CTLA-4 and PD-1 in pancreatic cancer. Gene expression of all examined costimulatory molecules was significantly upregulated in pancreatic cancer tissues. B7-1, B7-2, B7-H1, and B7-DC protein was detectable in pancreatic cancer cells. Only the expression of B7-H1 significantly correlated with postoperative survival (p<0.0001). B7-H1 was inducible in cultured pancreatic cancer cells by IFN-gamma and significantly correlated with the level of IFN-gamma expression in human pancreatic cancer tissues (Spearman rho=0.4536,p=0.0029). B7-H1 positive tumors showed an increased prevalence of tumor-infiltrating regulatory T cells (Tregs) compared to B7-H1 negative tumors. Among the investigated costimulatory molecules only tumor-associated B7-H1 seems to be of prognostic relevance in pancreatic cancer. B7-H1 might, therefore, be involved in the downregulation of antitumor responses through regulation of Tregs in pancreatic cancer. Our findings also suggest a dual role of IFN-gamma in antitumor response. Through induction of B7-H1 in pancreatic cancer cells IFN-gamma might contribute to the evasion of antitumor immunity.

PubMed Disclaimer

Similar articles

• Human decidual stromal cells suppress cytokine secretion by allogenic CD4+ T cells via PD-1 ligand interactions.
  Nagamatsu T, Schust DJ, Sugimoto J, Barrier BF. Nagamatsu T, et al. Hum Reprod. 2009 Dec;24(12):3160-71. doi: 10.1093/humrep/dep308. Epub 2009 Sep 3. Hum Reprod. 2009. PMID: 19729380
• B7-H1 expression on non-small cell lung cancer cells and its relationship with tumor-infiltrating lymphocytes and their PD-1 expression.
  Konishi J, Yamazaki K, Azuma M, Kinoshita I, Dosaka-Akita H, Nishimura M. Konishi J, et al. Clin Cancer Res. 2004 Aug 1;10(15):5094-100. doi: 10.1158/1078-0432.CCR-04-0428. Clin Cancer Res. 2004. PMID: 15297412
• Tumor-expressed B7-H1 and B7-DC in relation to PD-1+ T-cell infiltration and survival of patients with cervical carcinoma.
  Karim R, Jordanova ES, Piersma SJ, Kenter GG, Chen L, Boer JM, Melief CJ, van der Burg SH. Karim R, et al. Clin Cancer Res. 2009 Oct 15;15(20):6341-7. doi: 10.1158/1078-0432.CCR-09-1652. Epub 2009 Oct 13. Clin Cancer Res. 2009. PMID: 19825956
• B7-1 and B7-2: similar costimulatory ligands with different biochemical, oligomeric and signaling properties.
  Bhatia S, Edidin M, Almo SC, Nathenson SG. Bhatia S, et al. Immunol Lett. 2006 Apr 15;104(1-2):70-5. doi: 10.1016/j.imlet.2005.11.019. Epub 2005 Dec 13. Immunol Lett. 2006. PMID: 16413062 Review.
• Implications of B7-H1 expression in clear cell carcinoma of the kidney for prognostication and therapy.
  Thompson RH, Dong H, Kwon ED. Thompson RH, et al. Clin Cancer Res. 2007 Jan 15;13(2 Pt 2):709s-715s. doi: 10.1158/1078-0432.CCR-06-1868. Clin Cancer Res. 2007. PMID: 17255298 Review.

Cited by

• Modulation of PD-L1 by Astragalus polysaccharide attenuates the induction of melanoma stem cell properties and overcomes immune evasion.
  Yu H, Ding G, Gong Q, Ma J, Zhao Y, Wang Y, Qiao X, Cheng X. Yu H, et al. BMC Cancer. 2024 Aug 21;24(1):1034. doi: 10.1186/s12885-024-12788-4. BMC Cancer. 2024. PMID: 39169294 Free PMC article.
• Combination systemic therapies with immune checkpoint inhibitors in pancreatic cancer: overcoming resistance to single-agent checkpoint blockade.
  Gong J, Hendifar A, Tuli R, Chuang J, Cho M, Chung V, Li D, Salgia R. Gong J, et al. Clin Transl Med. 2018 Oct 8;7(1):32. doi: 10.1186/s40169-018-0210-9. Clin Transl Med. 2018. PMID: 30294755 Free PMC article. Review.
• Clinical significance of B7-H1 and B7-1 expressions in pancreatic carcinoma.
  Wang L, Ma Q, Chen X, Guo K, Li J, Zhang M. Wang L, et al. World J Surg. 2010 May;34(5):1059-65. doi: 10.1007/s00268-010-0448-x. World J Surg. 2010. PMID: 20145927
• Constitutive AP-1 activity and EBV infection induce PD-L1 in Hodgkin lymphomas and posttransplant lymphoproliferative disorders: implications for targeted therapy.
  Green MR, Rodig S, Juszczynski P, Ouyang J, Sinha P, O'Donnell E, Neuberg D, Shipp MA. Green MR, et al. Clin Cancer Res. 2012 Mar 15;18(6):1611-8. doi: 10.1158/1078-0432.CCR-11-1942. Epub 2012 Jan 23. Clin Cancer Res. 2012. PMID: 22271878 Free PMC article.
• Single-cell RNA sequencing to characterize the response of pancreatic cancer to anti-PD-1 immunotherapy.
  Zhou J, Jiang Y, Huang Y, Wang Q, Kaifi JT, Kimchi ET, Chabu CY, Liu Z, Joshi T, Li G. Zhou J, et al. Transl Oncol. 2022 Jan;15(1):101262. doi: 10.1016/j.tranon.2021.101262. Epub 2021 Nov 9. Transl Oncol. 2022. PMID: 34768100 Free PMC article.

MeSH terms

Substances

LinkOut - more resources

• Full Text Sources

  • ClinicalKey
  • Elsevier Science

• Other Literature Sources

  • The Lens - Patent Citations Database

• Medical

  • MedlinePlus Health Information

• Research Materials

  • NCI CPTC Antibody Characterization Program